Dermskin s.r.o.

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Psoriasis5 trials
• Atopic dermatitis (eczema)2 trials

Phase

• Phase 37 trials

Status

• Completed3 trials
• Active, not recruiting2 trials
• Not yet recruiting2 trials

Lead sponsor

• Alumis Inc2 trials
• Takeda2 trials
• Bristol-Myers Squibb1 trial
• Hunan Mabgeek Biotech Co. Ltd.1 trial
• Nektar Therapeutics1 trial

Running trials

• Not yet recruiting

  A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

  2025-525022-35-00· Phase 3· Hunan Mabgeek Biotech Co. Ltd.· Source

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07690371· Phase 3· Nektar Therapeutics· Source

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Alumis Inc· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atopic dermatitis (eczema)2 recruiting

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Takeda· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Alumis Inc· Source

• Completed

  Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

  NCT04036435· Phase 3· Bristol-Myers Squibb· Source